Grant of Share Options under Share Option Scheme

RNS Number : 6999I
Hutchison China Meditech Limited
15 December 2020
 

Grant of Share Options under Share Option Scheme

 

London: Tuesday, December 15, 20 20 : Hutchison China MediTech Limited ("Chi-Med") (Nasdaq /AIM : HCM) announces that on December 14, 20 20, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med   at its Annual General Meeting on April 24, 2015 (the "Share Option Scheme").  The scheme limit of the Share Option Scheme was refreshed on April 27, 2020. 

 

Chi-Med granted share options under its Share Option Scheme to employees to subscribe for a total of 1,535,580 Ordinary Shares represented by 307,116 American Depositary Shares ("ADSs") (each equating to five Ordinary Shares) subject to the acceptance of the grantees.  Details of such share options granted prescribed are as follows:

 

Date of grant

:

December 14 , 2020

 

Exercise price of share options granted

:

US$29 per ADS

 

Number of share options granted

:

1,535,580 represented by 307,116 ADSs (five share options shall entitle the holder thereof to subscribe for one ADS)

 

Closing market price of ADSs on the date of grant

 

:

US$29 per ADS

 

Validity period of the share options

:

From December 14, 2020 to December 13, 2030

 

Among the share options granted, a total of 58,570 share options represented by 11,714 ADSs were granted to Mr Christian Hogg and Dr Weiguo Su (Executive Directors of the Company), being persons discharging managerial responsibility under the EU Market Abuse Regulation as follows:-

 

Grantee


Number of share options granted




Mr Christian Hogg (Executive Director and Chief Executive Officer)


39,610 Ordinary Shares represented by 7,922 ADSs

 

Dr Weiguo Su (Executive Vice President and Chief Scientific Officer)


18,960 Ordinary Shares represented by 3,792 ADSs

 

 

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

 

(a)  Mr Christian Hogg

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

 

Name

 

Mr Christian Hogg

 

2

Reason for the notification

 

a)

 

Position/status

 

Executive Director and Chief Executive Officer

 

 

b)

 

Initial notification/Amendment

 

 

Initial notification

 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Hutchison China MediTech Limited

 

b)

 

 

LEI

 

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Option over American Depositary Share (each equating to five Ordinary Shares of US$0.10)

 

 

Option over American Depositary Share with ADS ISIN: US44842L1035

 

 

b)

 

Nature of the transaction

 

 

Grant of options in respect of 39,610 Ordinary Shares represented by 7,922 ADSs under the Share Option Scheme.

 

The share options granted are exercisable subject to a vesting schedule of 25% on each of the first, second, third and fourth anniversaries of the effective date of grant.

 

 

c)

 

Price(s) and volume(s)

 

Price(s)

Volume(s)

Nil

7,922



 

d)

 

Aggregated information

-

Aggregated volume

-

Price

 

N/A

 

e)

 

Date of the transaction

 

2020-12-14

 

 

f)

 

Place of the transaction

 

Outside a trading venue

 

 

(b) Dr Weiguo Su

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

 

Name

 

Dr Weiguo Su

 

2

Reason for the notification

 

a)

 

Position/status

 

Executive Director and Chief Scientific Officer

 

 

b)

 

Initial notification/Amendment

 

 

Initial notification

 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Hutchison China MediTech Limited

 

b)

 

 

LEI

 

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Option over American Depositary Share (each equating to five Ordinary Shares of US$0.10)

 

 

Option over American Depositary Share with ADS ISIN: US44842L1035

 

 

b)

 

Nature of the transaction

 

 

Grant of options in respect of 18,960 Ordinary Shares represented by 3,792 ADSs under the Share Option Scheme.

 

The share options granted are exercisable subject to a vesting schedule of 25% on each of the first, second, third and fourth anniversaries of the effective date of grant.

 

 

c)

 

Price(s) and volume(s)

 

Price(s)

Volume(s)

Nil

3,792



 

d)

 

Aggregated information

-

Aggregated volume

-

Price

 

N/A

 

e)

 

Date of the transaction

 

2020-12-14

 

 

f)

 

Place of the transaction

 

Outside a trading venue

 

 

 

About Chi-Med

 

Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.  It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

Forward-Looking Statements

 

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995.  Forward-looking statements involve risks and uncertainties.  Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM.  Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

 

 

CONTACTS

 

Investor Enquiries

 

Mark Lee, Senior Vice President

+852   2121   8200

Annie Cheng, Vice President

+1   (973)   567   3786



Media Enquiries

 

Americas - Brad Miles, Solebury Trout

+1   (917)   570   7340   (Mobile) 
bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw, FTI Consulting

+44   20   3727   1030 / +44   7771   913   902   (Mobile) / +44 7779 545 055 (Mobile)
Chi-Med@fticonsulting.com

Asia - Joseph Chi Lo / Zhou Yi, Brunswick

+852   9850   5033 (Mobile), jlo@brunswickgroup.com / +852   97 83   6894 (Mobile), y zhou@brunswickgroup.com



Nominated Advisor


Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited

+44   (20)   7886   2500



 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGPGWWPUPUUBA
UK 100